AMXT1501

DRUG2 trials

Sponsors

Aminex Therapeutics, Inc.

Conditions

Advanced CancerBreast CancerCancerCervical CancerColorectal CancerDIPG Brain TumorDiffuse Midline Glioma, H3 K27M-MutantEndometrial Cancer

Phase 1

Oral AMXT 1501 Dicaprate in Combination With DFMO

CompletedNCT03536728

Aminex Therapeutics, Inc.Advanced Cancer, Cancer, Solid Carcinoma +1

Start: 2018-06-12End: 2023-04-21Updated: 2023-05-25

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

TerminatedNCT05500508

Aminex Therapeutics, Inc.Advanced Cancer, Breast Cancer, Cancer +17

Start: 2022-11-29End: 2024-12-12Updated: 2024-12-24

Related Papers

Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism.

2025-09-061 citations

MDB-61. STARVING TUMORS OF POLYAMINES: A NOVEL APPROACH IN TREATING AGGRESSIVE PEDIATRIC MEDULLOBLASTOMA

Neuro-Oncology2024-06-18

Abstract B047: Inhibition of the polyamine pathway: a novel therapeutic approach to treat aggressive pediatric medulloblastoma

Cancer Research2024-03-04

Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.

2024-01-1011 citations

Abstract B132: Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone

Molecular Cancer Therapeutics2023-12-011 citations

DIPG-15. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA

Neuro-Oncology2020-12-011 citations